,i  #aaeth ,,congress  #b;d ,session    
,h4 ,r4 #eehb  ,,in ,,the ,,house ,,of  
,,representatives  ,april #bc1 #bjah    
,mr4 ,carter of ,georgia 7for himself1  
,mr4 ,loebsack1 and ,mr4 ,reed7         
introduced the following bill2 which was
 referred to the ,committee on ,energy  
and ,commerce1 and in addition to the   
,committee on ,ways and ,means1 for a   
period to be subsequently determined by 
the ,speaker1 in each case for          
consideration of such provisions as fall
 within the jurisdiction of the         
committee concerned  ,a ,,bill  ,to     
direct the ,secretary of ,health and    
,human ,services to conduct a study and 
submit a report on barriers to accessing
 abuse-deterrent opioid formulations for
 individuals enrolled in a plan under   
part ,c or ,d of the ,medicare program4 
#a4 ,short title ,this ,act may be cited
 at the ,abuse ,deterrent ,access ,act  
of #bjah4  #b4 ,study on abuse-deterrent
 opioid formulations access barriers    
under ,medicare  7a7 ,in general ,not   

later than #ahj days after the date of  
the enactment of this ,act1 the         
,secretary of ,health and ,human        
,services shall conduct a study and     
submit to ,congress a report on the     
adequacy of access to abuse-deterrent   
opioid formulations for individuals with
 chronic pain enrolled in an ,,ma-,,pd  
plan under part ,c of title ,,xviii of  
the ,social ,security ,act or a         
prescription drug plan under part ,d of 
such title of such ,act1 taking into    
account any barriers preventing such    
individuals from accessing such         
formulations under such ,,ma-,,pd or    
part ,d plans1 such as cost-sharing     
tiers1 fail-first requirements1 and     
prior authorization requirements4  7b7  
,definition of abuse-deterrent opioid   
formulation ,in this section1 the term  
abuse-deterrent opioid formulation means
 an opioid with certain abuse-deterrent 
properties1 such as physical or chemical
 barriers1 agonist or antagonist        
combinations1 aversion properties1      

delivery system mechanisms1 or other    
features designed to prevent abuse of   
such opioid4